Pharmacology of imatinib (STI571)
References (58)
- et al.
The hallmarks of cancer
Cell
(2000) - et al.
The molecular biology of chronic myeloid leukemia
Blood
(2000) - et al.
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
The Lancet
(2001) - et al.
ARG tyrosine kinase activity is inhibited by STI571
Blood
(2001) - et al.
Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor
Blood
(2000) - et al.
Involvement of platelet-derived growth factor in disease: development of specific antagonists
Adv Cancer Res
(2001) - et al.
Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines
J Biol Chem
(1991) - et al.
TEL/PDGFBR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
Blood
(1999) - et al.
Beta 1 integrinmediated collagen gel contraction is stimulated by PDGF
Exp Cell Res
(1990) - et al.
Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors
Blood
(1992)
Mutations in exons 9 and 13 of kit gene are rare events in gastrointestinal stromal tumors
Am J Pathol
(2000)
Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors
Am J Pathol
(2000)
The protein tyrosine kinase family of the human genome
Oncogene
(2000)
The protein tyrosine kinase family of the human genome
Oncogene
(2000)
Effects of a selective inhibitor of the Abl tyrosine-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
Cancer Res
(1996)
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Nat Med
(1996)
Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
New Engl J Med
(2001)
Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metatstatic gastrointestinal tumors (GSIT), and EORTC Phase I study
STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC Phase I study
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
J Pharmacol Exp Ther
(2000)
Chromosomal location, exon structure and vascular expression patterns of the human PDGFC and PDGFD genes
Circulation
(2001)
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyridine class
Cancer Res
(2000)
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
Cancer Res
(1992)
Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
Int J Cancer
(1995)
Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus
Cancer Res
(1998)
Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant
Mol Cell Biol
(1993)
Dominant negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells
Mol Cell Biol
(1993)
The dermatofibrosarcoma protuberans-associated collagen type 1alpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB
Cancer Res
(1999)
Cited by (237)
DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia
2022, Molecular and Cellular ProteomicsProtein kinase inhibitors and cancer targeted therapy
2022, Protein Kinase Inhibitors: From Discovery to TherapeuticsSynthesis and biological evaluation of pyranocarbazole derivatives as Anti-tumor agents
2021, Bioorganic and Medicinal Chemistry Letters
Copyright © 2003 Published by Elsevier Ltd.